- Home
- JXG vs ICU Comparison
JXG vs ICU Comparison
Compare JXG & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | ICU |
|---|---|---|
| Founded | N/A | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 15.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JXG | ICU |
|---|---|---|
| Price | $4.48 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.2K | ★ 147.9K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $46,835,624.00 | $881,000.00 |
| Revenue This Year | N/A | $691.85 |
| Revenue Next Year | N/A | $64.17 |
| P/E Ratio | $0.80 | ★ N/A |
| Revenue Growth | 21.68 | ★ 1195.59 |
| 52 Week Low | $3.01 | $2.20 |
| 52 Week High | $49.95 | $30.70 |
Technical Indicators
Market Signals| Indicator | JXG | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 68.83 |
| Support Level | $3.88 | $2.26 |
| Resistance Level | $4.74 | $2.98 |
| Average True Range (ATR) | 0.57 | 0.24 |
| MACD | -0.25 | 0.00 |
| Stochastic Oscillator | 21.69 | 40.54 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.